Search Results - "EELDE, A."

Validation of a composite score for clinical severity of hemophilia by SCHULMAN, S., EELDE, A., HOLMSTRÖM, M., STÅHLBERG, G., ODEBERG, J., BLOMBÄCK, M.

“…Introduction: Evaluation of modulators of the phenotypic expression of hemophilia may benefit from a scoring system that reflects several aspects of the…”
Get full text

Studies of microparticles in patients with the antiphospholipid syndrome (APS) by Vikerfors, A, Mobarrez, F, Bremme, K, Holmström, M, Ågren, A, Eelde, A, Bruzelius, M, Antovic, A, Wallén, H, Svenungsson, E

“…Objectives: To study circulating platelet, monocyte and endothelial microparticles (PMPs, MMPs and EMPs) in patients with antiphospholipid syndrome (APS) in…”
Get full text

Confusion around the official classification of arthropathy by SCHULMAN, S., EELDE, A.

Get full text

The plasma concentration of activated protein C appears normal in patients with haemophilia by SCHULMAN, S., EELDE, A., BLOMBÄCK, M., STENFLO, J.

“…Increased concentration of activated protein C (APC) has been observed in patients with thromboembolic disorders, but whether the level of APC in patients with…”
Get full text

Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A by Antovic, J., Schulman, S., Eelde, A., Blombäck, M.

“…Pro‐thrombin‐activatable fibrinolysis inhibitor (pro‐TAFI), also known as TAFI, procarboxypeptidase U, or procarboxypeptidase B, is a relatively recently…”
Get full text

Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy by Majeed, Ammar, Eelde, Anna, Ågren, Anna, Schulman, Sam, Holmström, Margareta

“…Abstract Background There is uncertainty regarding the efficacy and incidence of thromboembolic events in patients treated with prothrombin complex…”
Get full text

A ROTEM method using APTT reagent and tissue factor as the clotting activators may better define bleeding heterogeneity in moderate or severe haemophilia A (part I: Study in plasma samples) by He, Shu, Eelde, Anna, Petrini, Pia, Wallen, Håkan, Gabrielsson, Lena, Svensson, Jan, Blombäck, Margareta, Holmström, Margareta

“…Bleeding heterogeneity observed in haemophilia A (HA) may attribute to that the available monitoring methods cannot appropriately reflect the coagulation…”
Get full text

Thrombin activatable fibrinolysis inhibitor (TAFI) — A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS) by Grosso, Giorgia, Vikerfors, Anna, Woodhams, Barry, Adam, Mariette, Bremme, Katarina, Holmström, Margareta, Ågren, Anna, Eelde, Anna, Bruzelius, Maria, Svenungsson, Elisabet, Antovic, Aleksandra

“…Thrombosis and complement activation are pathogenic features of antiphospholipid syndrome (APS). Their molecular link is Plasma carboxypeptidase-B, also known…”
Get full text

Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome by Vikerfors, Anna, Svenungsson, Elisabet, Ågren, Anna, Mobarrez, Fariborz, Bremme, Katarina, Holmström, Margareta, Eelde, Anna, Bruzelius, Maria, Elgue, Graciela, Wallén, Håkan, Antovic, Aleksandra

“…Abstract Objective The antiphospholipid syndrome (APS) is defined by persistent antiphospholipid antibodies together with thrombosis and/or pregnancy…”
Get full text

Using minute doses of APTT reagent and tissue factor as the coagulation trigger to quantify the coagulation profile in hemophilia A by He, S, Eelde, A, Petrini, P, Blomback, M

Get full text

Studies of microparticles in patients with antiphospholipid syndrome (APS) by Vikerfors, A, Mobarrez, F, Bremme, K, Holmstrom, M, Agren, A, Eelde, A, Bruzelius, M, Antovic, A, Wallen, H, Svenungsson, E

Get full text

The Case for Holland by van Eelde, A. G. A.

Get full text